Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00343577 · ClinicalTrials.gov registry record

Antiproteinuric Agents and Fabry Disease

A clinical trial of Fabry Disease and Proteinuria, sponsored by University of Alabama at Birmingham.

Completed
Registry status
12
Enrollment target
1
Study location

NCT00343577: Completed study of Fabry Disease and Proteinuria, sponsored by University of Alabama at Birmingham.

NCT00343577 is a study of Fabry Disease and Proteinuria that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 12 participants, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00343577, a study of Fabry Disease and Proteinuria, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
12 participants
Enrollment target
1
Study location

Study Summary

Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion. Proteinuria is recognized as an important risk factor for progression of chronic kidney disease. Our hypothesis is that using drugs that reduce urine protein excretion (ACE inhibitors and ARBs) will have a beneficial effect on patients with Fabry disease who already are receiving enzyme replacement therapy. A longitudinal, observational study is being undertaken to determine the utility of these agents in Fabry disease, realizing that these agents are primarily indicated for reducing systemic blood pressure, and most patients with Fabry disease have relatively low blood pressures at baseline.

Conditions Studied

Fabry Disease Proteinuria

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2001-01
Est. Completion 2006-12
University of Alabama at Birmingham

1,160 total trials

What the finished NCT00343577 record still lists

NCT00343577 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 542-participant average among 32 other Fabry Disease trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Fabry Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00343577 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT00343577 about?

NCT00343577 is a clinical study titled "Antiproteinuric Agents and Fabry Disease". Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion. Proteinuria is recognized as an important risk factor for progression of chronic kidney disease. Our hypothesis is that using drugs that reduce urine protein excretion (ACE inhibitors and ARBs)...

What is the current status of trial NCT00343577?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2001-01. Estimated completion is 2006-12.

What conditions does trial NCT00343577 study?

This clinical trial studies the following conditions: Fabry Disease, Proteinuria.

Who is sponsoring clinical trial NCT00343577?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00343577 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fabry Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00343577's enrollment target sits among peer trials

12 29th of 32 higher than 3 of 32 other Fabry Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fabry Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00343577, the US trial registry maintained by the National Library of Medicine. NCT00343577 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.